<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00112151</url>
  </required_header>
  <id_info>
    <org_study_id>02-1056</org_study_id>
    <secondary_id>R01AG019339</secondary_id>
    <nct_id>NCT00112151</nct_id>
  </id_info>
  <brief_title>TEAM: Testosterone Supplementation and Exercise in Elderly Men</brief_title>
  <official_title>Testosterone Supplementation and Exercise in Elderly Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of testosterone supplementation
      (AndroGel) on body composition, strength, endurance, cognition, and function in older men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies suggest that testosterone (T) replacement in healthy elderly men has beneficial
      effects on body composition, muscle, bone, memory, and behavior, but the risks of chronic
      treatment, especially on the prostate, heart, and sleep quality, are not entirely clear.
      Therefore, it is most desirable to supplement into the lowest &quot;effective&quot; range in elderly
      men. However, the effects of lower than usual replacement T doses have not been well studied.
      Furthermore, the possible important interaction of exercise to enhance the positive effects
      of T supplementation, yet mitigate the possible side effects, has not been studied in older
      men.

      This one-year study will enroll 150 men with low-normal to slightly below normal serum total
      T levels. Participants will be randomized into one of 6 treatment groups to receive T
      supplementation (AndroGel) of 25mg/day, 50 mg/day or a placebo crossed with progressive
      resistance training (PRT) exercise 3 times a week versus none. At the end of the study,
      participants in the exercise-control group will be offered PRT.

      Please see link below for updated version of full protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Function (CS-PFP Total Score)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Continuous-scale physical function performance test (CS-PFP) which comprises 15 everyday tasks requiring upper and lower body strength and flexibility, balance, coordination and endurance. The CS-PFP was developed to measure performance in higher functioning adults with minimal floor or ceiling effects, and is valid, reliable and sensitive to change. Total and domain scores are scaled from 0 to 100, with higher scores indicating better function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper Body Muscle Strength (1-RM, kg)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The maximal weight a participant could lift once (1-repetition maximum, 1-RM) was assessed at baseline and 12 months. The average of the difference from baseline in 4 upper-body 1-RM measures (bench press,incline press, overhead pull-down, and seated row) are represented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Body Muscle Strength (1-RM, kg)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The maximal weight a participant could lift once [1-repetition maximum, 1-RM] was assessed at baseline and 12 months. The average of the difference from baseline in 3 lower-body 1-RM measures (knee extension, knee flexion, and seated leg press)) are represented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Power (Power Rig, Watts)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Leg extensor power was evaluated using a Nottingham leg extensor power rig (watts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Mass (kg)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Total change in Fat mass (kg) as evaluated by DXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Free Mass (kg)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Total change in Fat free mass (kg) as evaluated by DXA</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LowT+Resistance Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)
1 year standard Progressive Resistance Training(PRT) program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LowT+No Resistance training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)
No exercise program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HighT+Resistance Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)
1 year standard Progressive Resistance Training(PRT) program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HighT+No Resistance Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)
No exercise program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Resistance Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo Group applies two 2.5 gm placebo packets
1 year standard Progressive Resistance Training(PRT) program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+No Resistance Training</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group applies two 2.5 gm placebo packets
No exercise program</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LowT</intervention_name>
    <description>Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.</description>
    <arm_group_label>LowT+Resistance Training</arm_group_label>
    <arm_group_label>LowT+No Resistance training</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Resistance Training</intervention_name>
    <description>Weight training 45-60 minutes 3 times per week</description>
    <arm_group_label>LowT+Resistance Training</arm_group_label>
    <arm_group_label>HighT+Resistance Training</arm_group_label>
    <arm_group_label>Placebo+Resistance Training</arm_group_label>
    <other_name>PRT</other_name>
    <other_name>Progressive resistance training</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.</description>
    <arm_group_label>Placebo+Resistance Training</arm_group_label>
    <arm_group_label>Placebo+No Resistance Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HighT</intervention_name>
    <description>High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.</description>
    <arm_group_label>HighT+Resistance Training</arm_group_label>
    <arm_group_label>HighT+No Resistance Training</arm_group_label>
    <other_name>Androgel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy, untrained men 60 years or older with low-normal testosterone levels
             (200-350ng/dL)

          -  Must reside in the Denver metro area

        Exclusion Criteria:

          -  Prostate/breast cancer

          -  Unable to exercise safely

          -  severe obesity (&gt;34 body mass index [BMI])

          -  Polycythemia

          -  Diabetes

          -  Use of drugs that could affect T levels

          -  Cognitive dysfunction (MMSE less than 24)

          -  PSA above the age-adjusted normal level or AUA greater than 19

          -  Unable to pass stress test due to active CAD
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S. Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://som-hcpr.ucdenver.edu/Ger-ClinicalTrials/team/TeamProtocol-v2.0.pdf</url>
    <description>Current Protocol</description>
  </link>
  <link>
    <url>http://som-hcpr.ucdenver.edu/Ger-ClinicalTrials/team/TeamAnalysisPlan2011-03-07.pdf</url>
    <description>Analysis Plan for Primary Results</description>
  </link>
  <link>
    <url>http://som-hcpr.ucdenver.edu/Ger-ClinicalTrials/team/TeamAbstract.pdf</url>
    <description>Testosterone Supplementation and Exercise in Elderly Men Abstract</description>
  </link>
  <reference>
    <citation>Schwartz RS, Shuman WP, Bradbury VL, Cain KC, Fellingham GW, Beard JC, Kahn SE, Stratton JR, Cerqueira MD, Abrass IB. Body fat distribution in healthy young and older men. J Gerontol. 1990 Nov;45(6):M181-5.</citation>
    <PMID>2229940</PMID>
  </reference>
  <reference>
    <citation>Porter MM, Vandervoort AA, Lexell J. Aging of human muscle: structure, function and adaptability. Scand J Med Sci Sports. 1995 Jun;5(3):129-42. Review.</citation>
    <PMID>7552755</PMID>
  </reference>
  <reference>
    <citation>Jolles J, Verhey FR, Riedel WJ, Houx PJ. Cognitive impairment in elderly people. Predisposing factors and implications for experimental drug studies. Drugs Aging. 1995 Dec;7(6):459-79. Review.</citation>
    <PMID>8601053</PMID>
  </reference>
  <reference>
    <citation>Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab. 1983 Jul;57(1):71-7.</citation>
    <PMID>6602143</PMID>
  </reference>
  <reference>
    <citation>Vitiello MV. Sleep disorders and aging: understanding the causes. J Gerontol A Biol Sci Med Sci. 1997 Jul;52(4):M189-91. Review.</citation>
    <PMID>9224429</PMID>
  </reference>
  <reference>
    <citation>Myers BL, Badia P. Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions. Neurosci Biobehav Rev. 1995 Winter;19(4):553-71. Review. Erratum in: Neurosci Biobehav Rev 1996 Summer;20(2):I-IV.</citation>
    <PMID>8684716</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2005</study_first_submitted>
  <study_first_submitted_qc>May 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2005</study_first_posted>
  <results_first_submitted>November 4, 2015</results_first_submitted>
  <results_first_submitted_qc>December 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2016</results_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>andropause</keyword>
  <keyword>hypogonadism</keyword>
  <keyword>AndroGel</keyword>
  <keyword>exercise</keyword>
  <keyword>PRT</keyword>
  <keyword>Testosterone</keyword>
  <keyword>T supplementation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from January 2005 through August 2009 of community dwelling men &gt;=60 years of age in the Denver metropolitan area with active attempts to recruit men from all ethnic populations.</recruitment_details>
      <pre_assignment_details>see eligibility criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LowT+Resistance Training</title>
          <description>Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)
1 year standard Progressive Resistance Training(PRT) program</description>
        </group>
        <group group_id="P2">
          <title>LowT+No Resistance Training</title>
          <description>Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)
No exercise program</description>
        </group>
        <group group_id="P3">
          <title>HighT+Resistance Training</title>
          <description>High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)
1 year standard Progressive Resistance Training(PRT) program</description>
        </group>
        <group group_id="P4">
          <title>HighT+No Resistance Training</title>
          <description>High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)
No exercise program</description>
        </group>
        <group group_id="P5">
          <title>Placebo+Resistance Training</title>
          <description>Placebo Group applies two 2.5 gm placebo packets
1 year standard Progressive Resistance Training(PRT) program</description>
        </group>
        <group group_id="P6">
          <title>Placebo+No Resistance Training</title>
          <description>Placebo group applies two 2.5 gm placebo packets
No exercise program</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LowT+Resistance Training</title>
          <description>Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)
1 year standard Progressive Resistance Training(PRT) program</description>
        </group>
        <group group_id="B2">
          <title>LowT+No Resistance Training</title>
          <description>Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)
No exercise program</description>
        </group>
        <group group_id="B3">
          <title>HighT+Resistance Training</title>
          <description>High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)
1 year standard Progressive Resistance Training(PRT) program</description>
        </group>
        <group group_id="B4">
          <title>HighT+No Resistance Training</title>
          <description>High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)
No exercise program</description>
        </group>
        <group group_id="B5">
          <title>Placebo+Resistance Training</title>
          <description>Placebo Group applies two 2.5 gm placebo packets
1 year standard Progressive Resistance Training(PRT) program</description>
        </group>
        <group group_id="B6">
          <title>Placebo+No Resistance Training</title>
          <description>Placebo group applies two 2.5 gm placebo packets
No exercise program</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="28"/>
            <count group_id="B6" value="28"/>
            <count group_id="B7" value="167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="7.6"/>
                    <measurement group_id="B2" value="65.6" spread="4.5"/>
                    <measurement group_id="B3" value="64.3" spread="4.6"/>
                    <measurement group_id="B4" value="65.3" spread="5.5"/>
                    <measurement group_id="B5" value="64.7" spread="4.5"/>
                    <measurement group_id="B6" value="66.6" spread="5.4"/>
                    <measurement group_id="B7" value="65.7" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Physical Function (CS-PFP Total Score)</title>
        <description>Continuous-scale physical function performance test (CS-PFP) which comprises 15 everyday tasks requiring upper and lower body strength and flexibility, balance, coordination and endurance. The CS-PFP was developed to measure performance in higher functioning adults with minimal floor or ceiling effects, and is valid, reliable and sensitive to change. Total and domain scores are scaled from 0 to 100, with higher scores indicating better function.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + No PRT</title>
            <description>Placebo gel; no exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PRT</title>
            <description>Placebo gel plus progressive resistance training</description>
          </group>
          <group group_id="O3">
            <title>Any T + No PRT</title>
            <description>T gel supplementation (lower or higher-range); no exercise</description>
          </group>
          <group group_id="O4">
            <title>Any T + PRT</title>
            <description>T gel supplementation (lower or higher-range) plus progressive resistance training</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Function (CS-PFP Total Score)</title>
          <description>Continuous-scale physical function performance test (CS-PFP) which comprises 15 everyday tasks requiring upper and lower body strength and flexibility, balance, coordination and endurance. The CS-PFP was developed to measure performance in higher functioning adults with minimal floor or ceiling effects, and is valid, reliable and sensitive to change. Total and domain scores are scaled from 0 to 100, with higher scores indicating better function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="6.7"/>
                    <measurement group_id="O2" value="3.6" spread="8.0"/>
                    <measurement group_id="O3" value="0.8" spread="7.3"/>
                    <measurement group_id="O4" value="3.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (any T). The primary analysis was conducted in the PRT groups and compared CS-PFP at 12 months with any T to placebo, adjusted for baseline CS-PFP score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.025</p_value>
            <p_value_desc>A one-sided P-value of &lt;0.025 was used to define statistical significance</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (any T). To address whether the effects of any T on physical function are the same without PRT, the analysis was also conducted in the No PRT groups, comparing CS-PFP at 12 months with any T to placebo, adjusted for baseline CS-PFP score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.025</p_value>
            <p_value_desc>A one-sided P-value of &lt;0.025 was used to define statistical significance.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Upper Body Muscle Strength (1-RM, kg)</title>
        <description>The maximal weight a participant could lift once (1-repetition maximum, 1-RM) was assessed at baseline and 12 months. The average of the difference from baseline in 4 upper-body 1-RM measures (bench press,incline press, overhead pull-down, and seated row) are represented.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + No PRT</title>
            <description>Placebo gel; no exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PRT</title>
            <description>Placebo gel plus progressive resistance training</description>
          </group>
          <group group_id="O3">
            <title>Any T + No PRT</title>
            <description>T gel supplementation (lower- or higher-range); no exercise</description>
          </group>
          <group group_id="O4">
            <title>Any T + PRT</title>
            <description>T gel supplementation (lower- or higher-range) plus progressive resistance training</description>
          </group>
        </group_list>
        <measure>
          <title>Upper Body Muscle Strength (1-RM, kg)</title>
          <description>The maximal weight a participant could lift once (1-repetition maximum, 1-RM) was assessed at baseline and 12 months. The average of the difference from baseline in 4 upper-body 1-RM measures (bench press,incline press, overhead pull-down, and seated row) are represented.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="7.7"/>
                    <measurement group_id="O2" value="25.5" spread="11.3"/>
                    <measurement group_id="O3" value="7.8" spread="6.9"/>
                    <measurement group_id="O4" value="24.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in average upper body strength with any T to placebo in subjects assigned to PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in average upper body strength with any T to placebo in subjects assigned to no PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lower Body Muscle Strength (1-RM, kg)</title>
        <description>The maximal weight a participant could lift once [1-repetition maximum, 1-RM] was assessed at baseline and 12 months. The average of the difference from baseline in 3 lower-body 1-RM measures (knee extension, knee flexion, and seated leg press)) are represented.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + No PRT</title>
            <description>Placebo gel; no exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PRT</title>
            <description>Placebo gel plus progressive resistance training</description>
          </group>
          <group group_id="O3">
            <title>Any T + No PRT</title>
            <description>T gel supplementation (lower- or higher-range); no exercise</description>
          </group>
          <group group_id="O4">
            <title>Any T + PRT</title>
            <description>T gel supplementation (lower- or higher-range) plus progressive resistance training</description>
          </group>
        </group_list>
        <measure>
          <title>Lower Body Muscle Strength (1-RM, kg)</title>
          <description>The maximal weight a participant could lift once [1-repetition maximum, 1-RM] was assessed at baseline and 12 months. The average of the difference from baseline in 3 lower-body 1-RM measures (knee extension, knee flexion, and seated leg press)) are represented.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="11.6"/>
                    <measurement group_id="O2" value="27.0" spread="17.0"/>
                    <measurement group_id="O3" value="10.5" spread="10.9"/>
                    <measurement group_id="O4" value="28.0" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in average lower body strength with any T to placebo in subjects assigned to PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in average lower body strength with any T to placebo in subjects assigned to no PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Power (Power Rig, Watts)</title>
        <description>Leg extensor power was evaluated using a Nottingham leg extensor power rig (watts).</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + No PRT</title>
            <description>Placebo gel; no exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PRT</title>
            <description>Placebo gel plus progressive resistance training</description>
          </group>
          <group group_id="O3">
            <title>Any T + No PRT</title>
            <description>T gel supplementation (lower- or higher-range); no exercise</description>
          </group>
          <group group_id="O4">
            <title>Any T + PRT</title>
            <description>T gel supplementation (lower- or higher-range) plus progressive resistance training</description>
          </group>
        </group_list>
        <measure>
          <title>Power (Power Rig, Watts)</title>
          <description>Leg extensor power was evaluated using a Nottingham leg extensor power rig (watts).</description>
          <units>Watts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="34.6"/>
                    <measurement group_id="O2" value="24.3" spread="62.0"/>
                    <measurement group_id="O3" value="0.8" spread="36.9"/>
                    <measurement group_id="O4" value="5.1" spread="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in leg extensor power with any T to placebo in subjects assigned to PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in leg extensor power with any T to placebo in subjects assigned to no PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Mass (kg)</title>
        <description>Total change in Fat mass (kg) as evaluated by DXA</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + No PRT</title>
            <description>Placebo gel; no exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PRT</title>
            <description>Placebo gel plus progressive resistance training</description>
          </group>
          <group group_id="O3">
            <title>Any T + No PRT</title>
            <description>T gel supplementation (lower- or higher-range); no exercise</description>
          </group>
          <group group_id="O4">
            <title>Any T + PRT</title>
            <description>T gel supplementation (lower- or higher-range) plus progressive resistance training</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Mass (kg)</title>
          <description>Total change in Fat mass (kg) as evaluated by DXA</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.3"/>
                    <measurement group_id="O2" value="-0.6" spread="1.7"/>
                    <measurement group_id="O3" value="-1.0" spread="2.3"/>
                    <measurement group_id="O4" value="-1.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in fat mass measured by dual x-ray absorptiometry (DXA) with any T to placebo in subjects assigned to PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in fat mass measured by dual x-ray absorptiometry (DXA) with any T to placebo in subjects assigned to no PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Free Mass (kg)</title>
        <description>Total change in Fat free mass (kg) as evaluated by DXA</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo + No PRT</title>
            <description>Placebo gel; no exercise</description>
          </group>
          <group group_id="O2">
            <title>Placebo + PRT</title>
            <description>Placebo gel plus progressive resistance training</description>
          </group>
          <group group_id="O3">
            <title>Any T + No PRT</title>
            <description>T gel supplementation (lower- or higher-range); no exercise</description>
          </group>
          <group group_id="O4">
            <title>Any T + PRT</title>
            <description>T gel supplementation (lower- or higher-range) plus progressive resistance training</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Free Mass (kg)</title>
          <description>Total change in Fat free mass (kg) as evaluated by DXA</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.7"/>
                    <measurement group_id="O2" value="0.4" spread="2.1"/>
                    <measurement group_id="O3" value="1.0" spread="2.2"/>
                    <measurement group_id="O4" value="2.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in fat free mass measured by dual x-ray absorptiometry (DXA) with any T to placebo in subjects assigned to PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>As prespecified, the lower- and higher-range T groups were combined (Any T). The analysis compared change from baseline to 12 months in fat free mass measured by dual x-ray absorptiometry (DXA) with any T to placebo in subjects assigned to no PRT.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Systematic assessments were done at baseline, 4, 12, 26 and 52 weeks. As prespecified, adverse events were analyzed according to T dosing (e.g. placebo, lower-range T, and higher-range T).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo gel with or without progressive resistance training</description>
        </group>
        <group group_id="E2">
          <title>Lower-range T</title>
          <description>T gel supplementation targeting a total serum T concentration of 400-550ng/dL, with our without progressive resistance training</description>
        </group>
        <group group_id="E3">
          <title>Higher-range T</title>
          <description>T gel supplementation targeting a total serum T concentration of 600-1000ng/dL, with our without progressive resistance training</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Total serious cardiovascular adverse events</sub_title>
                <description>Includes acute coronary syndrome, arrhythmia, aortic aneurysm, syncope/presyncope</description>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other noncardiovascular serious adverse events</sub_title>
                <counts group_id="E1" events="53" subjects_affected="20" subjects_at_risk="47"/>
                <counts group_id="E2" events="55" subjects_affected="31" subjects_at_risk="47"/>
                <counts group_id="E3" events="64" subjects_affected="37" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Persistently elevated HCT &gt;= 54%</sub_title>
                <description>Polycythemia or persistent elevated hematocrit &gt;= 54%</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other nonserious adverse events</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Other nonserious adverse events</description>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Persistently elevated liver function tests</sub_title>
                <description>Alanine aminotransferase or aspartate aminotransferase &gt; 2 times the upper limit of normal</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Persistently elevated PSA</sub_title>
                <description>Persistent elevated PSA representing an increase of &gt;=0.75 ng/mL over baseline</description>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" events="13" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Elevated AUA</sub_title>
                <description>American Urological Association (AUA) BPH Symptom Score Index &gt;= 20</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Daytime somnolence/hypoxia</sub_title>
                <description>Somnolence = Epworth Sleepiness Score &gt; 16; hypoxia is daytime arterial oxygen saturation by pulse oximetry &lt; 88%</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert S. Schwartz, Head, Division of Geriatric Medicine</name_or_title>
      <organization>Univeristy of Colorado at Denver</organization>
      <phone>303-724-1919</phone>
      <email>robert.schwartz@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

